VBU
3-chloranyl-6-(4-methylpiperazin-1-yl)-11~{H}-benzo[b][1,4]benzodiazepine
Find entries where: VBU
is present as a standalone ligand in 1 entries
Chemical Component Summary | |
---|---|
Name | 3-chloranyl-6-(4-methylpiperazin-1-yl)-11~{H}-benzo[b][1,4]benzodiazepine |
Synonyms | Clozapine |
Identifiers | 3-chloranyl-6-(4-methylpiperazin-1-yl)-11~{H}-benzo[b][1,4]benzodiazepine |
Formula | C18 H19 Cl N4 |
Molecular Weight | 326.823 |
Type | NON-POLYMER |
Isomeric SMILES | CN1CCN(CC1)C2=Nc3cc(ccc3Nc4c2cccc4)Cl |
InChI | InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3 |
InChIKey | QZUDBNBUXVUHMW-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 42 |
Chiral Atom Count | 0 |
Bond Count | 45 |
Aromatic Bond Count | 12 |
Drug Info: DrugBank
DrugBank ID | DB00363 |
---|---|
Name | Clozapine |
Groups | approved |
Description | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent.[A256708] Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".[A256723]. This low affinity to dopamine receptors results in fewer extrapyramidal side effects, especially tardive dyskinesia.[A185747] However, its promiscuity toward the muscarinic and adrenergic receptors can result in other side effects, notably gastrointestinal hypomotility and orthostatic hypotension. [L905,A215552]. Despite its effectiveness in treating both positive and negative symptoms of schizophrenia, clozapine was briefly removed from the market in various jurisdictions in 1970 due to severe agranulocytosis.[A256713,A256718] However, continued evidence of its effectiveness led to clozapine's eventual reintroduction, although with a reluctance to prescribe it.[A256718] Clozapine was approved by the FDA in 1989 for treatment-resistant schizophrenia under the brand CLOZARIL.[L905] Due to its severe adverse effects profile, clozapine is only available through a restricted program under a Risk Evaluation Mitigation Strategy (REMS) called the Clozapine REMS Program.[L905] |
Synonyms |
|
Brand Names |
|
Indication | Clozapine is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine should be used only in patients who have failed to respond adequately to standard antipsychotic treatment.[L905] Clozapine is also indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. Suicidal behavior refers to actions by a patient that put him/herself at risk for death.[L905] |
Categories |
|
ATC-Code | N05AH02 |
CAS number | 5786-21-0 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Dopamine D1 receptor | MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIR... | unknown | antagonist |
Dopamine D2 receptor | MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF... | unknown | antagonist |
Dopamine D3 receptor | MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV... | unknown | antagonist |
Dopamine D4 receptor | MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLA... | unknown | antagonist |
Dopamine D5 receptor | MLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLL... | unknown | binder |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL42 |
PubChem | 135398737 |
ChEMBL | CHEMBL42 |
ChEBI | CHEBI:3766, CHEBI:92657 |
CCDC/CSD | DEHBUP, NDNHCL10 |